Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NES3
UPID:
LFNG_HUMAN
Alternative names:
O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
Alternative UPACC:
Q8NES3; B3KTY6; B5MCR5; O00589; Q96C39; Q9UJW5
Background:
Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe, also known as O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, plays a pivotal role in the modulation of NOTCH signaling. By initiating the elongation of O-linked fucose residues on EGF-like repeats in Notch molecules, it intricately regulates NOTCH1 activity. This modulation is crucial for somite segmentation and patterning, highlighting its significance in developmental biology.
Therapeutic significance:
The protein's involvement in Spondylocostal dysostosis 3, an autosomal recessive condition characterized by severe skeletal malformations, underscores its therapeutic potential. Understanding the role of Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe could open doors to potential therapeutic strategies for this and related disorders.